Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 15/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 12/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811056 | 1.00 | SLC5A2 (0.42) | SLC5A2SLC5A1POLBAPLNRCA2 | |
| SCHEMBL4809775 | 0.84 | SLC5A2 (0.38) | SLC5A2SLC5A1ALDH1A1 | |
| SCHEMBL4809778 | 0.84 | SLC5A2 (0.38) | SLC5A2SLC5A1ALDH1A1 | |
| SCHEMBL4805362 | 0.81 | SLC5A1 (0.40) | SLC5A2SLC5A1 | |
| SCHEMBL4815023 | 0.81 | PTGER1 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL4805370 | 0.81 | SLC5A1 (0.40) | SLC5A2SLC5A1 | |
| SCHEMBL4815015 | 0.81 | PTGER1 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL4810903 | 0.80 | SLC5A2 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL4810911 | 0.80 | SLC5A2 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL4812073 | 0.79 | SLC5A2 (0.53) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414072-B2 | Aryl 5-thio-β-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-19 | — | — | US | disclosed |
| US-20050209309-A1 | Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-22 | — | — | US | disclosed |
| EP-1528066-A1 | ARYL 5-THIO-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209309-A1 | Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same | SLC5A2, SLC5A1, UGGT1 | SLC5A2 1/4885SLC5A1 2/4885POLB 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.